Linnea P. Cipriano

Linnea Cipriano is a partner in Goodwin's Intellectual Property Litigation group. Her practice focuses on patent litigation in federal courts and the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).

Linnea has particular expertise in litigation and counseling in the pharmaceutical industry, including preparing for and representing clients in district court litigation under the Hatch-Waxman Act and BPCIA. Linnea’s experience extends to patents in the broader life science industry, including nutritional supplements, chemical manufacturing, DNA-based technology, medical devices, and drug delivery technologies.

Linnea also focuses her practice on post grant proceedings at the PTAB and has represented clients in both inter partes review (IPR) and post grant review (PGR) proceedings. Linnea has represented petitioners and patent owner’s in a wide variety of technologies, including pharmaceutical formulations, electronic devices, manufacturing methods, and medical devices.

Linnea’s practice combines her in-depth knowledge of patent law with her scientific experience to serve her clients. She holds a graduate degree in pharmacology, and before pursuing a career in law, performed research at the Cleveland Clinic.

Representative matters include:

• Consult clients in tech and life science industries regarding strategy for filing and defending against PTAB challenges.
• Glux Visual Effects Tech (Shenzhen) Co. et al. v. Ultravision Technologies, LLC (IPR2020-01049, -01050, and -01052):  Lead Counsel for Petitioners in three IPRs successfully challenging patents related to digital displays.
• Slayback Pharma LLC v. Eye Therapies, LLC (IPR2022-00142 and -00146): Lead counsel for petitioner in two IPRs related to eye drop formulations.
• Tris Pharma, Inc. v. Teva Pharmaceuticals (D.N.J.): Representing Teva in Hatch-Waxman litigation related to a generic version of a drug product for the treatment of ADHD.
• Fresenius Kabi USA, LLC v. Novo Nordisk A/S (IPR2022-00657): Lead counsel for petitioner challenging patents related to peptide formulations.
• Par Pharmaceutical, Inc., et al. v. Amneal Pharmaceuticals of New York, LLC, et al. (D. Del.): Representing Amneal in a patent infringement case related to a generic drug product for the treatment of hypotension.
• Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, IPR2020-01317, -01318, IPR2012-00816: Representing Patent Owner defending against IPR challenges to Novartis’s patent related to a pre-filled syringe.
• Representing Fresenius Kabi in multiple IPR and PGR proceedings at the PTAB.
• Representing Celltrion at the PTAB and in patent infringement litigations related to Celltrion’s rituximab and trastuzumab biosimilars.
• Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc. et al. (D.N.J.): Representing Actavis at trial in a patent infringement case related to a generic antifungal drug.
• Tris Pharma, Inc. v. Actavis Labs. FL, Inc. (D. Del.): Representing Actavis at trial and on an appeal in a patent infringement case related to a generic version of a drug product for the treatment of ADHD.
• Intendis GmbH, et al. v. Glenmark Generics Limited et al. (D. Del.): Representing Glenmark at trial and on appeal in a patent infringement case related to a generic drug product for the treatment of rosacea. 
• Warner Chilcott Co., LLC et al. v. Teva Pharmaceuticals USA, Inc. (D.N.J.): Representing Teva at trial and on appeal in a patent infringement case related to a generic drug product for the treatment of osteoporosis.

Linnea’s pro bono work includes:

• Representing American Bird Conservancy in a case brought under the federal Environmental Protection Act against New York State Department of Parks, Recreation, and Historic Preservation regarding protection of Piping Plovers in Jones Beach State Park.
• Representing an individual applying for political asylum in the U.S.
• Representing unaccompanied minors in family court and in petitions to USCIS

Prior to joining Goodwin, Linnea was an associate in the New York office of Kenyon & Kenyon. She also worked as a legal intern at Cleveland Clinic Innovations and as a research technologist at the Cleveland Clinic Foundation.

Linnea serves on the Board of NYIPLA. She is the Board liaison to NYIPLA’s Women in IP Law committee and is a member of the ChIPs Network.

Linnea was named as a recommended lawyer for The IAM Patent 1000 New York Litigation 2022.

Linnea was a 2021 recommended lawyer for Patent litigation: full coverage by The Legal 500.

Linnea was selected to the Super Lawyers New York Metro Rising Stars list in 2015-2021.

• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Co-Author, “Key PTAB Priorities And changes Under Vidal,” Law 360, June 2023
• Co-Author, “3 Best Practices For Patent Claims Against Secret Methods,” Law360, August 12, 2019
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019

Linnea is the managing editor of the Goodwin PTAB Trial Tracker periodic newsletter.